ArticleFrontiers in microbiology2017
The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against
Open access · goldAbstract read
In one paragraph
Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 82 citations in OpenAlex.
- Article
- Cellular and molecular responses ofMicrobiology spectrum · 2026Article
- Design, synthesis, and biological evaluation of a focused pyrrolo- and pyrido-quinazolinone natural products-templated library for anti-fungal and anthelmintic activities.Bioorganic & medicinal chemistry · 2026Article
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans.PLoS neglected tropical diseases · 2025Article
- Antifungal Activity of 8-Hydroxyquinoline Derivatives AgainstPathogens (Basel, Switzerland) · 2025Article
- Insights from Mass Spectrometry-Based Proteomics onJournal of fungi (Basel, Switzerland) · 2025Review
- Colistin enhances caspofungin antifungal efficacy against Aspergillus fumigatus by modulating calcium homeostasis and stress responses.Nature communications · 2025Article
- Growth of nematophagous fungi in the presence of anthelmintics drugs.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Preparation and pharmacokinetic study of mebendazole complex with HP-beta-cyclodextrin.Frontiers in veterinary science · 2025Article
- Unleashing Fungicidal Forces: Exploring the Synergistic Power of Amphotericin B-Loaded Nanoparticles and Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2024Article
- Corrected and republished from: "Extracellular Vesicle Formation inInfection and immunity · 2024Article
- In vitro effects of selective serotonin reuptake inhibitors on Cryptococcus gattii capsule and biofilm.Pathogens and disease · 2024Article
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.Infection and drug resistance · 2024Review
- Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis.PloS one · 2024Article
- Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.Folia microbiologica · 2023Article
- Naphthylthiazoles: a class of broad-spectrum antifungals.RSC medicinal chemistry · 2023Article
- Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.Journal of fungi (Basel, Switzerland) · 2023Article
- Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023Review
- A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Luna S JoffeLaboratório de Biologia Celular de Leveduras Patogênicas, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro Rio de Janeiro, Brazil.
Rafael SchneiderCentro de Biotecnologia, Universidade Federal do Rio Grande do Sul Porto Alegre, Brazil.
William LopesCentro de Biotecnologia, Universidade Federal do Rio Grande do Sul Porto Alegre, Brazil.
Renata AzevedoFundação Oswaldo Cruz - Fiocruz, Centro de Desenvolvimento Tecnológico em Saúde Rio de Janeiro, Brazil.
Charley C StaatsCentro de Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil; Departamento de Biologia Molecular e Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil.
Lívia KmetzschCentro de Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil; Departamento de Biologia Molecular e Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil.
Augusto SchrankCentro de Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil; Departamento de Biologia Molecular e Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil.
Maurizio Del PoetaVeterans Administration Medical Center, NorthportNY, USA; Department of Molecular Genetics and Microbiology, Stony Brook University, Stony BrookNY, USA.
Marilene H VainsteinCentro de Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil; Departamento de Biologia Molecular e Biotecnologia, Universidade Federal do Rio Grande do SulPorto Alegre, Brazil.
Marcio L RodriguesLaboratório de Biologia Celular de Leveduras Patogênicas, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de JaneiroRio de Janeiro, Brazil; Fundação Oswaldo Cruz - Fiocruz, Centro de Desenvolvimento Tecnológico em SaúdeRio de Janeiro, Brazil.
Universidade Federal do Rio Grande do Sul · BRFundação Oswaldo Cruz · BRStony Brook University · USUniversidade Federal do Rio de Janeiro · BR
Funding
New antifungals targeting the synthesis of fungal sphingolipidsR01AI116420 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI Maurizio Del Poeta · 2016 to 2026
$7.6MLipid-mediated fungal pathogenesisR01AI125770 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2016 to 2025
$6.2MSphingosine-1-phosphate and cryptococcosisR01AI136934 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2018 to 2022
$2.5MNIAID NIH HHS R01 AI116420NIAID NIH HHS R01 AI125770NIAID NIH HHS R01 AI136934Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
antifungalantifungal targetsbenzimidazolesbiofilmCryptococcus neoformansmacrophagesmebendazole
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.